Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 975 results for death

  1. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

    Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.

  2. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  3. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.

  4. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  5. Dupilumab for treating moderate to severe atopic dermatitis (TA534)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.

  6. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

  7. Percutaneous cryotherapy for renal cancer (HTG269)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

  8. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  9. CareLink network service for remote monitoring of people with cardiac devices (MIB64)

    NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices

  10. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

  11. Processed nerve allografts to repair peripheral nerve discontinuities (HTG454)

    Evidence-based recommendations on processed nerve allografts to repair peripheral nerve discontinuities. This involves using a specially treated nerve (an allograft) taken from a human donor after death to bridge the gap in the nerve.

  12. Needle-free arterial non-injectable connector (MIB85)

    NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .

  13. Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)

    Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.

  14. Endoscopic stapling of pharyngeal pouch (HTG8)

    Evidence-based recommendations on endoscopic stapling of pharyngeal pouch. This involves stapling the opening of the pharyngeal pouch through a specially designed endoscope.

  15. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.